Methionine metabolism and endocrine function of the pituitary gland in patients with suprasellar germinoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
01
2023
accepted:
27
06
2023
medline:
17
7
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the association between methionine (MET) metabolism and endocrine function of the pituitary gland in patients with suprasellar region tumor. Twenty patients with intracranial germinoma were included in this study. Initial staging and all surveillance MET PET/CT scans and comparable serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH) were analyzed. The patients were divided into two groups according to tumor location, with tumors in the suprasellar region (condition) or not (control). MET uptake of the pituitary gland (i.e., SUVR [standardized uptake value ratio]) and levels of FSH, LH, TSH were compared in the condition and control groups and in the before and after treatment phases of each group. The SUVR in the control group was like that found in normal pituitary glands in previous studies, whereas the SUVR of the untreated condition group was high and that of treated condition group was low with significance compared to the control group. Serum levels of pituitary hormones in before and after treatment condition groups were significantly lower than those in the control group. The FSH and LH levels of curatively treated patients in the control group were positively correlated with SUVR with respective ß values of 3.71 and 0.98 (p < .001). The TSH level of the treated condition group was negatively correlated with SUVR (ß = -1.02, p < .001). This study is the first known investigation to examine the association between MET metabolism and endocrine function of the pituitary gland, and it confirmed that MET metabolism reflects endocrine function. A future study validating the result of correlation analysis is warranted.
Identifiants
pubmed: 37440573
doi: 10.1371/journal.pone.0288528
pii: PONE-D-23-01882
pmc: PMC10343025
doi:
Substances chimiques
Luteinizing Hormone
9002-67-9
Follicle Stimulating Hormone
9002-68-0
Thyrotropin
9002-71-5
Methionine
AE28F7PNPL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0288528Informations de copyright
Copyright: © 2023 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuro Oncol. 2013 Jun;15(6):788-96
pubmed: 23460321
Pediatr Neonatol. 2021 Jan;62(1):106-112
pubmed: 33218934
Biom J. 2006 Apr;48(2):286-301
pubmed: 16708779
Cancer Res Treat. 2017 Apr;49(2):494-501
pubmed: 27554477
Lancet Diabetes Endocrinol. 2015 Jul;3(7):568-76
pubmed: 25873572
Neurol Med Chir (Tokyo). 1993 Mar;33(3):152-7
pubmed: 7683121
J Nucl Med. 2007 Dec;48(12):1971-80
pubmed: 18006617
Ann Nucl Med. 2014 Feb;28(2):94-102
pubmed: 24272066
Acta Radiol. 2017 Mar;58(3):362-366
pubmed: 27273374
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73
pubmed: 12692687
J Neurooncol. 2012 Aug;109(1):115-22
pubmed: 22528799
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35
pubmed: 23232505